Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) as a Response Monitoring Tool in Patients With High-Risk Prostate Cancer Receiving Neoadjuvant Therapy

NCT06384222 is registered in ClinicalTrials.gov with Ivan de Kouchkovsky, MD as lead sponsor.

NCT NCT06384222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06384222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) as a Response Monitoring Tool in Patients With High-Risk Prostate Cancer Receiving Neoadjuvant Therapy
Lead sponsor
Ivan de Kouchkovsky, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 9, 2024
Completion date
April 30, 2031
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk prostate carcinoma, prostate cancer